Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5.17M
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-13.3M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$956K
-
Number of sells
-
-19
Significant Holders of CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) as of Q1 2025
19 filings reported holding CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 5.17M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include Revolve Wealth Partners, LLC (0 shares), SG Americas Securities, LLC (0 shares), FNY Investment Advisers, LLC (0 shares), HBK Sorce Advisory LLC (0 shares), Avantax Planning Partners, Inc. (0 shares), JPMORGAN CHASE & CO (0 shares), Vanguard Personalized Indexing Management, LLC (0 shares), Guidance Point Advisors, LLC (0 shares), Tower Research Capital LLC (TRC) (0 shares), and Selkirk Management LLC (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.